| Minerva Neuroscie (NERV) | |||
|---|---|---|---|
| 2.34 -0.03 (-1.27%) | 05-06 16:00 | ||
| Open: | 2.41 | Pre. Close: | 2.37 |
| High: | 2.41 | Low: | 2.34 |
| Volume: | 9,261 | Market Cap: | 16(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 3.04 One year: 3.27 |
| Support: | Support1: 2.29 Support2: 1.90 |
| Resistance: | Resistance1: 2.60 Resistance2: 2.80 |
| Pivot: | 2.44 |
| Moving Averages: | MA(5): 2.36 MA(20): 2.46 MA(100): 5.22 MA(250): 6.47 |
| MACD: | MACD(12,26): -0.19  Signal(12,26,9): -0.24 |
| %K %D: | %K(14,3): 11.51 %D(3): 14.95 |
| RSI: | RSI(14): 32.38 |
| 52-Week: | High: 13.49 Low: 2.286 Change(%): -60.1 |
| Average Vol(K): | 3-Month: 111 10-Days: 10 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 2.416 - 2.428 | 2.428 - 2.437 |
| Low: | 2.307 - 2.323 | 2.323 - 2.336 |
| Close: | 2.318 - 2.342 | 2.342 - 2.361 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NERV ] has closed above bottom band by 11.8%. Bollinger Bands are 90.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 6.99 |
| Shares Float (M) | 5.44 |
| % Held by Insiders | 22.26 |
| % Held by Institutions | 34.94 |
| Shares Short (K) | 30 |
| Shares Short Prior Month (K) | 38 |
| Stock Financials | |
|---|---|
| EPS | -4.610 |
| Book Value (p.s.) | -5.230 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -29.9 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -3.498 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -20.76 |
| Levered Free Cash Flow (M) | -18.41 |
| Stock Valuation | |
|---|---|
| PE Ratio | -0.51 |
| PEG Ratio | |
| Price to Book value | -0.45 |
| Price to Sales | |
| Price to Cash Flow | -0.79 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
